Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.
Precision BioSciences, a US-based genomic medicine developer spun out from Duke University, completed a $110m series B round yesterday that included the institution’s endowment arm Duke Management Company.
Spinout-focused investment firm Osage University Partners also contributed to the round, as did pharmaceutical firms Amgen and EMS, and real estate investment trust Alexandria Real Estate Equities.
Franklin Templeton Investments, Cowen Healthcare Investments, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Ridgeback Capital, Agent Capital, VenBio, F-Prime, RA Capital Management, Longevity Fund and entities affiliated with Leerink Partners also invested.
The corporates participated through their respective investment subsidiaries, Amgen Ventures, Brace Pharma Capital and Alexandria Venture Investments. Precision BioSciences revealed it had secured $88m towards the round earlier this month.
Founded in 2006, Precision has developed a genome editing platform intended to be used in immuno-oncology and genetic disease treatments as well as the food…
